In this study, although the sample size was small due to limited number of OI patients, it would suggest that aptscl56 could bind to both recombinant sclerostin and the circulating sclerostin in human via targeting loop3, implying the potential of aptscl56 as a translational medicine for OI patients. Here, SOST is linked to osteogenesis imperfecta.